These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 20088944)

  • 1. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
    Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
    J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
    Morishima Y; Honda Y
    J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
    Incampo F; Carrieri C; Semeraro N; Colucci M
    Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
    Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
    J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
    Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.
    Semeraro F; Ammollo CT; Semeraro N; Colucci M
    Haematologica; 2009 Jun; 94(6):819-26. PubMed ID: 19377079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visualization of Domain- and Concentration-Dependent Impact of Thrombomodulin on Differential Regulation of Coagulation and Fibrinolysis.
    Mochizuki L; Sano H; Honkura N; Masumoto K; Urano T; Suzuki Y
    Thromb Haemost; 2023 Jan; 123(1):16-26. PubMed ID: 36307100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
    Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
    Mao SS; Holahan MA; Bailey C; Wu G; Colussi D; Carroll SS; Cook JJ
    Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood.
    Carrieri C; Galasso R; Semeraro F; Ammollo CT; Semeraro N; Colucci M
    J Thromb Haemost; 2011 Jan; 9(1):154-62. PubMed ID: 20961395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models.
    Leenaerts D; Loyau S; Mertens JC; Boisseau W; Michel JB; Lambeir AM; Jandrot-Perrus M; Hendriks D
    J Thromb Haemost; 2018 Oct; 16(10):2057-2069. PubMed ID: 30053349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.
    Schneider M; Nesheim M
    J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis.
    Morishima Y; Kamisato C; Honda Y
    J Thromb Thrombolysis; 2020 Jan; 49(1):94-99. PubMed ID: 31396790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
    Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
    Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
    Bajzar L; Nesheim ME; Tracy PB
    Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII.
    Nielsen VG; Kirklin JK
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):793-800. PubMed ID: 19002046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by paradoxical enhancement of thrombin generation: comparison with a direct factor Xa inhibitor edoxaban.
    Morishima Y; Kamisato C; Honda Y
    Blood Coagul Fibrinolysis; 2021 Apr; 32(3):209-215. PubMed ID: 33560005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
    Guimarães AH; Barrett-Bergshoeff MM; Criscuoli M; Evangelista S; Rijken DC
    Thromb Haemost; 2006 Sep; 96(3):325-30. PubMed ID: 16953274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.